Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.
Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease.
Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.
At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.
†
ColoAlert, Lead Product Highlights
Significant Impact
Revenue Generating
ColoAlert has received CE accreditation and is approved for sale in Europe. European sales provide near-term revenue potential, while we prepare our entry into the US market.
Upside Potential
Experienced Management
Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.
1 Colorectal cancer is the second leading cause of cancer death in the US – Cancer.org
2 Sensitivity is the ability of a test to correctly identify those with the disease (true positive rate), whereas test specificity is the ability of the test to correctly identify those without the disease (true negative rate).
3 As defined in ColoAlert instructions for use.
(a) See more information here
(b) See more information here
MAINZ BIOMED (NASDAQ: MYNZ) AIMS TO BECOME A LEADER IN THE MULTI-BILLION-DOLLAR COLORECTAL CANCER DIAGNOSTICS MARKET
Sorry, we couldn't find any posts. Please try a different search.
Title | Last Updated | File Size | View |
---|---|---|---|
Board Rules: Mainz Biomed | 30th October 2021 | 300KB | |
Audit Committee Charter | 30th October 2021 | 326KB | |
Compensation Committee Charter | 30th October 2021 | 138KB | |
Nomination Committee Charter | 30th October 2021 | 151KB |
Title | Last Updated | File Size | View |
---|---|---|---|
Code of Ethics and Business Conduct | 30th October 2021 | 130KB | |
Remuneration Policy | 30th October 2021 | 185KB | |
Remuneration Proposal | 30th October 2021 | 146KB |
To contact our Investor Relations team, send us a message using the form or use one of the other methods below.
Suspendisse et blandit nibh. Donec sed erat tempor, vulputate felis at, molestie mi. Proin vitae laoreet purus. Aliquam tempor vestibulum tristique. Ut mollis dui et ante congue, quis consectetur erat venenatis. Nulla eget tempor augue, id porta arcu. Vestibulum vulputate semper augue id condimentum. Ut malesuada vitae diam ut venenatis. Etiam sed erat eu eros fermentum facilisis sit amet sed elit. Curabitur luctus dapibus eleifend. Proin eget mauris velit. Maecenas tincidunt erat ex, efficitur euismod tortor aliquam vel. Ut nec diam et ligula aliquet finibus nec a massa. Etiam at dolor sem. Morbi viverra orci sollicitudin enim sollicitudin, quis lobortis justo pretium. Phasellus ligula eros, hendrerit sed luctus a, pharetra vel arcu.
Aenean commodo, lectus id faucibus fermentum, velit felis euismod turpis, et fermentum turpis ante gravida mauris. Aenean id magna at erat interdum feugiat eu id erat. Duis sed nisi in ex sollicitudin suscipit. Curabitur hendrerit elementum lectus in volutpat. Aenean iaculis, risus ut consequat hendrerit, purus diam tristique mauris, nec consectetur magna tortor quis lectus. Proin varius pulvinar mi at congue. Curabitur non nisl nisl. Fusce ultrices malesuada dui, quis ultrices enim rutrum fermentum.
Q4 2020 – FILING TYPE A
Q3 2020 – FILING TYPE A
Q2 2020 – FILING TYPE A
Q1 2020 – FILING TYPE A
Q4 2019 – FILING TYPE A
Q3 2019 – FILING TYPE A
Q2 2019 – FILING TYPE A
Q1 2019 – FILING TYPE A
H2 2020 – FILING TYPE B
H1 2020 – FILING TYPE B
H2 2019 – FILING TYPE B
H1 2019 – FILING TYPE B
Suspendisse et blandit nibh. Donec sed erat tempor, vulputate felis at, molestie mi. Proin vitae laoreet purus. Aliquam tempor vestibulum tristique. Ut mollis dui et ante congue, quis consectetur erat venenatis. Nulla eget tempor augue, id porta arcu.
CONTACT INFORMATION
CONTACT INFORMATION
CONTACT INFORMATION
CONTACT INFORMATION
If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.